-VISIT OUR OTHER FORUMS- OB-GYN-L Ultrasound Ultrasound History Fibroid Forum Physicians-in-Training Tech Talk OBSTET-L (portuguese) OBGIN-L (spanish) Nursing

Re: OB: Mixed Reviews On Drug To Prevent Preterm Birth From: ainsron (ainsron@sbcglobal.net) Tue Aug 29 15:10:27 2006 Messages sorted by: [ date ][ thread ][ subject ][ author ] Next message: Dean Huffman .: "OB: Mixed Reviews On Drug To Prevent Preterm Birth" Previous message: Len2976@aol.com: "Re: OB: Mixed Reviews On Drug To Prevent Preterm Birth" In reply to: art fougner, md: "Re: OB: Mixed Reviews On Drug To Prevent Preterm Birth" Not to mention the liability we incur when we give the drug to a patient and it doesn't work, or when we give the drug to a patient and a complication occurs, or when we don't give the drug to a patient and they deliver prematurely or have a complication related to prematurity. I don't see much of a winning scenario for the OBs. Plus the insurers will consider the administration of the drug a non-reimbursable expense to the obstetrician, like the have with RhoGam, sonograms done in the office, etc. Ronald E. Ainsworth, MD, FACOG -----Original Message----- From: ob-gyn-l@obgyn.net [mailto:ob-gyn-l@obgyn.net] On Behalf Of art fougner, md Sent: Tuesday, August 29, 2006 12:44 PM To: Multiple recipients of list OB-GYN-L Subject: Re: OB: Mixed Reviews On Drug To Prevent Preterm Birth A lot more than they will reimburse the physician who administers the injection. Art At Tue, 29 Aug 2006, Charlie Chambers wrote: > >I wonder how much more they are going to charge for brand name >progesterone. > >On Aug 29, 2006, at 10:38 AM, art fougner, md wrote: > >> A drug to help women carry their babies to term that is awaiting >> federal >> approval doesn't appear to delay the earliest preterm births most >> often >> linked to death and serious health problems, according to federal >> documents released yesterday. >> >> The results of a single clinical trial were not "statistically >> persuasive" in suggesting that the injectable drug, Gestiva, reduced >> births before either 32 or 35 weeks' gestation, Food and Drug >> Administration documents show. >> >> However, the drug does appear to reduce births before the 37th week, >> considered the cutoff point for a newborn to be considered premature, >> study results suggest. Adeza Biomedical Corp. said in FDA filings >> that >> weekly injections of Gestiva lead to a "substantial reduction" in >> preterm births among women most at risk. >> >> http://www.newsday.com/news/health/ny- >> hspree294869380aug29,0,5906224.story >> >> Art >> >> -- >> art fougner, md >> "May The Wings of Liberty Never Lose a Feather." - Jack Burton -- art fougner, md "May The Wings of Liberty Never Lose a Feather." - Jack Burton Next message: Dean Huffman .: "OB: Mixed Reviews On Drug To Prevent Preterm Birth" Previous message: Len2976@aol.com: "Re: OB: Mixed Reviews On Drug To Prevent Preterm Birth" In reply to: art fougner, md: "Re: OB: Mixed Reviews On Drug To Prevent Preterm Birth"

Return to

Mail a New Message to the Forum: ob-gyn-l@obgyn.net Forum Administrator: geffrey.klein@obgyn.net Report Technical Problems: webmaster@obgyn.net Last Updated: Wed Jul 2 04:44:36 2008

The American Medical Association is no longer designating CME hours for AMA Category II CME credit. However, physicians themselves may self designate learning activities as Category II CME credit hours if they feel it is of sufficient educational merit and meets the formal definitions of continuing medical education. OBGYN.net believes these interaction in this forum meets these criteria. For further information see the AMA web site.